CD8A and neoplasm: Among mRCC patients treated with nivolumab, those with high tumor cells PD-L1 expression and a high percentage of CD8+ PD-1+ TIM-3- LAG-3- tumor-infiltrating cells experienced longer immune-related PFS and better immune-related ORR (60).